QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
about
Computational methods in drug discoveryDevelopment and validation of an automated high-throughput system for zebrafish in vivo screeningsOptimisation of embryonic and larval ECG measurement in zebrafish for quantifying the effect of QT prolonging drugsTargeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseasesADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockagePatterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform.Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.Screening the receptorome.Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsA new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels.hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.Medicinal chemical properties of successful central nervous system drugsIdentification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?A phenotypic in vitro model for the main determinants of human whole heart function.Effects of Tannic Acid, Green Tea and Red Wine on hERG Channels Expressed in HEK293 Cells.Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.Pharmacogenomics and acquired long QT syndrome.Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing.Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentialsMaximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodProbing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic aciRevealing the structural basis of action of hERG potassium channel activators and blockers.Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.Interactions at human ether-à-go-go-related gene channels.Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Core Replacements in a Potent Series of VEGFR-2 Inhibitors and Their Impact on Potency, Solubility, and hERG.Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis.A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.Rank order entropy: why one metric is not enough
P2860
Q26997089-3AB88200-2F4A-44CE-AAF7-FE10969FBD51Q27303272-BEA0C342-0705-4005-BF4B-E43F6F8442BEQ27330065-9E851B39-5DA7-467A-8D97-06793B9488B0Q28303760-F8EE811A-74F7-4320-821E-697AEC354101Q28730653-53A35636-F9F0-4385-A311-F5B2C2FC98CDQ30500502-668D923C-5D87-47BE-8676-DB71FC7F9F93Q30620268-F034E569-4C77-4050-AF6A-927961EA4F0AQ33167296-6A64BDAD-8D21-4B18-8C21-8F9D2100C006Q33247259-B7F738A4-4AE6-4829-9309-14E122A2937BQ33402040-82EE62FE-F0E6-468B-A28B-FCE98DF6FD2FQ33479407-DC5D198D-346A-4196-B0F8-9D61349B20EEQ33772055-4E9B757F-A0FE-4480-9D53-58FB082A8341Q33845924-1C8BC8E3-D104-4EB5-B920-C94BB9D3D020Q33933939-3CC4B8F9-4C7F-43E9-9666-4EDA6053FC50Q33946968-92E450EB-56FD-4951-B616-B0958F89E98FQ34407398-052371DE-908A-4EED-9CCF-C8173539355CQ34724614-F34D2D11-975A-435D-9389-F8B23DC67C7EQ35028720-6D16CF97-3DF4-4E32-83F9-CA97FB353416Q35236864-9B0FF4C8-1EDA-4C59-BA0C-21258050389DQ35690281-3349DEEA-8934-48B3-A9F3-8138D834782BQ35857269-8F244970-6A9F-4612-A57F-AA8DFD2FEAE5Q36054425-4E432084-57A3-4B56-A386-0D72E9B30837Q36147318-FB49DA3E-FDBC-4650-B7FC-785F7A28441DQ36150565-1AF8EE66-B574-4C82-AB85-DA82FB92F972Q36192679-6B7AAC2E-3FF1-4CC7-A0C2-857548885050Q36382928-00E17F7A-6364-485D-BA69-286203D73349Q36545039-7CFC71BB-C5B6-4161-80CA-BD9376EF1DCBQ36629300-1C5F33C0-7B3F-4712-8984-7BAEB11F91DFQ36960535-51729AAC-EA38-4A58-97C5-42B94A972334Q37156289-804460BB-C21D-4B3F-9A55-AE7DFC608337Q37464272-3FC0A241-E03A-48A3-8DFC-AFA1E2DF596DQ37774138-12B82DE9-F520-434E-8F86-7B5E9A5C3966Q38671689-2A2E07F2-4210-4B7B-BAD1-442B9B0B462FQ39752399-9432583F-ED14-4EC9-A828-ACE2463E88A0Q39816545-9DDF4DA5-5403-4317-AF3B-89B2DD58EADBQ40277384-0FBF8A7E-9815-401E-8509-4C58636F3D94Q40317287-6FA1241F-7E66-497E-A5EB-A034C9EC0565Q41376898-61061DF1-5606-436D-845F-40AE29CBCEE9Q41870587-84C30B9B-0591-4FFC-B079-B0EDE3D9B8FEQ42012988-D671CE40-162E-4DF3-890F-7C495AA9A48F
P2860
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
QT prolongation through hERG K ...... ction during drug development.
@ast
QT prolongation through hERG K ...... ction during drug development.
@en
type
label
QT prolongation through hERG K ...... ction during drug development.
@ast
QT prolongation through hERG K ...... ction during drug development.
@en
prefLabel
QT prolongation through hERG K ...... ction during drug development.
@ast
QT prolongation through hERG K ...... ction during drug development.
@en
P2860
P50
P356
P1476
QT prolongation through hERG K ...... ction during drug development.
@en
P2093
Andrea Cavalli
Maurizio Recanatini
P2860
P304
P356
10.1002/MED.20019
P577
2005-03-01T00:00:00Z